Skip to main content
Premium Trial:

Request an Annual Quote

Norman Dovichi, Annelise Barron, Patrick Doyle, Richard Lussier, Duncan Whitney, James LeVoy Sorenson

Premium
Genome Corp. of Providence, RI, announced its scientific advisory board this week, which includes Norman Dovichi, Annelise Barron, and Patrick Doyle.
 
Dovichi is a professor of analytical chemistry at the University of Washington. While at the University of Alberta, he developed sheath flow detection for capillary electrophoresis, one of the key technologies used in ABI’s 3700 sequencer.
 
Barron is an associate professor of bioengineering at Stanford University. She has developed several sieving matrices for Sanger sequencing (see feature article in this issue) and has published work on read lengths of more than 1,300 bases. Until recently, she was a faculty member at Northwestern University.
 
Doyle is an associate professor of chemical engineering at the Massachusetts Institute of Technology, where he studies the dynamics of biopolymers and complex fluids, including theoretical and empirical studies of DNA migration during electrophoresis.
 

 
Richard Lussier has become chief operating officer and general manager at Progenika Biopharma. Most recently, he was at Solexa, which Illumina acquired a year ago, where he built a worldwide field organization to sell the Genome Analyzer. Previously, he held a number of technical, marketing, and management positions at Applied Biosystems and Celera Genomics, including general manager of Applera’s Japanese subsidiary.
 
Duncan Whitney has become Progenika Biopharma’s CSO. Previously, he was vice president of research and development at US Genomics. Before that, he was vice president of technology development at Exact Sciences, where he was responsible for commercializing novel DNA-based colon cancer diagnostic tests. He also held various positions at PerSeptive Biosystems, which later became part of Applied Biosystems. Whitney holds an undergraduate degree in chemistry from Colby College and a PhD from the Massachusetts Institute of Technology.
 

 
James LeVoy Sorenson, a medical device inventor and founder of companies, including Sorenson Genomics and Sorenson Forensics, died of cancer on Sunday at the age of 86.
 
Among the companies he founded were Deseret Pharmaceuticals, which was later acquired by Becton Dickinson, and Sorenson Research, which was acquired by Abbott Laboratories.
 
He also founded the non-profit Sorenson Molecular Genealogy Foundation, which has built a collection of correlated genetic and family history information in more than 170 countries.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.